Fecal Calprotectin Test Market Driven by Rising Prevalence of Crohn’s Disease and Ulcerative Colitis

 The global fecal calprotectin test market is poised for substantial expansion over the next decade, reflecting the growing emphasis on non-invasive diagnostic tools for gastrointestinal disorders. According to the latest market projections, the sector is expected to record a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032. The market, valued at US$4,728.3 million in 2025, is anticipated to almost double, reaching a remarkable US$9,623.7 million by 2032. This growth trajectory underscores the increasing prevalence of gastrointestinal diseases, advancements in diagnostic testing technologies, and the rising awareness of early disease detection among healthcare professionals and patients worldwide.

Market Overview

Fecal calprotectin testing has emerged as a critical diagnostic tool in differentiating inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) and other gastrointestinal conditions. Calprotectin, a calcium-binding protein found in neutrophils, serves as a reliable biomarker for intestinal inflammation. The test’s non-invasive nature, coupled with its high sensitivity and specificity, has positioned it as a preferred diagnostic method among clinicians globally. The rising burden of gastrointestinal disorders, particularly IBD and colorectal cancer, is fueling demand for these tests across hospitals, diagnostic laboratories, and gastroenterology centers.

Key Market Drivers

The rising prevalence of inflammatory bowel disease (IBD) across developed and emerging markets remains a central growth driver. Factors such as changing dietary habits, sedentary lifestyles, and environmental influences have contributed to an increasing incidence of chronic gastrointestinal conditions. According to various global health organizations, millions of individuals are affected by Crohn’s disease and ulcerative colitis each year, spurring the demand for diagnostic solutions that enable early and accurate detection.

Another major driver is the growing preference for non-invasive diagnostic methods. Traditional diagnostic techniques such as colonoscopy are often invasive, costly, and associated with patient discomfort. Fecal calprotectin tests, in contrast, provide a convenient and accurate alternative, enabling physicians to screen patients and monitor disease progression effectively. Additionally, technological advancements in assay methods—including enzyme-linked immunosorbent assays (ELISA) and point-of-care testing—have enhanced diagnostic precision, further propelling market growth.

The integration of automated platforms in clinical laboratories and the increasing adoption of rapid test kits are also contributing to market expansion. Hospitals and diagnostic centers are investing in advanced testing systems to improve workflow efficiency and patient turnaround times. Furthermore, increased healthcare expenditure and the growing focus on preventive healthcare programs are supporting the uptake of fecal calprotectin tests worldwide.

Market Challenges

Despite its promising growth, the market faces several challenges. One of the key restraints is the lack of awareness in developing regions regarding gastrointestinal disease diagnostics. Limited access to advanced healthcare infrastructure in low- and middle-income countries may restrict market penetration. Additionally, variability in test results due to sample handling or assay differences can impact diagnostic accuracy, creating the need for standardized testing procedures.

The high cost associated with advanced diagnostic systems may also limit adoption, particularly in cost-sensitive markets. Moreover, reimbursement constraints and regulatory hurdles in certain regions could impede market expansion. Nonetheless, ongoing research and development activities aimed at improving test reliability and affordability are expected to mitigate these challenges over the forecast period.

Segmental Insights

By Technique
The market can be segmented by technique into enzyme-linked immunosorbent assay (ELISA), enzyme fluoroimmunoassay, immunochromatography, point-of-care tests, and others. Among these, ELISA-based tests hold a dominant share due to their established accuracy and wide clinical acceptance. They are extensively utilized in laboratories for the quantitative measurement of calprotectin levels. However, the point-of-care testing segment is expected to exhibit the fastest growth during the forecast period. The increasing demand for rapid and easy-to-use diagnostic solutions, especially in outpatient and remote healthcare settings, is driving this segment’s expansion. Immunochromatography and fluoroimmunoassay techniques are also gaining traction, supported by their ability to provide quick and reliable results for clinical decision-making.

By Indication
Based on indication, the fecal calprotectin test market is categorized into inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), colorectal cancer, infections, and others. The IBD segment commands the largest share, reflecting the rising global incidence of Crohn’s disease and ulcerative colitis. Early diagnosis and continuous monitoring are essential in managing these chronic inflammatory disorders, thereby propelling test demand. The IBS segment is projected to register significant growth as awareness about differentiating functional and inflammatory gastrointestinal conditions increases. Furthermore, the colorectal cancer segment is gaining importance with the rising emphasis on early detection and screening initiatives to reduce cancer-related mortality.

By End-user
The market, when analyzed by end-user, includes hospitals and clinics, diagnostic laboratories, research institutes, and gastroenterology centers. Diagnostic laboratories account for the majority of the market share due to their high testing volumes and advanced laboratory infrastructure. Hospitals and clinics also represent a substantial share, particularly as healthcare institutions increasingly integrate fecal calprotectin testing into standard diagnostic protocols. Gastroenterology centers and research institutes are expected to show notable growth, supported by ongoing clinical studies and innovations in biomarker-based diagnostics.

Regional Outlook

North America holds a dominant position in the global fecal calprotectin test market, driven by the high prevalence of gastrointestinal diseases, robust healthcare infrastructure, and extensive adoption of diagnostic technologies. The United States continues to lead the regional market, with significant investments in healthcare research and diagnostic innovation.

Europe follows closely, fueled by well-established laboratory networks, supportive regulatory frameworks, and high public awareness regarding gastrointestinal health. Countries such as Germany, the United Kingdom, and France are key contributors to regional growth.

East Asia is emerging as a lucrative market, with Japan, China, and South Korea at the forefront of diagnostic advancements. Growing healthcare expenditure and increasing efforts to improve disease detection rates are enhancing the market outlook in this region.

South Asia and Oceania represent a promising growth corridor due to the expanding healthcare sector, government initiatives for diagnostic development, and the presence of regional manufacturers offering cost-effective testing solutions.

Latin America and the Middle East and Africa are projected to witness steady growth, supported by improving healthcare infrastructure and a gradual rise in awareness of gastrointestinal disease management. While challenges such as limited access to advanced diagnostics persist, ongoing healthcare reforms are expected to create favorable market conditions in these regions.

Competitive Landscape

The global fecal calprotectin test market is characterized by strong competition and technological innovation. Key industry participants include Epitope Diagnostics Inc., Hycult Biotech, Actim, OPERON, Svar Life Science, BÜHLMANN, DRG International Inc., ALPCO, Diazyme Laboratories, Thermo Fisher Scientific Inc., and several others. These companies are actively engaging in strategic initiatives such as product launches, collaborations, mergers, and acquisitions to strengthen their market presence and expand their geographic reach.

Leading players are also focusing on enhancing assay performance, developing user-friendly kits, and integrating digital technologies to improve result interpretation and data management. Partnerships with healthcare providers and diagnostic laboratories are further enabling companies to capture larger market shares. Innovation remains a critical factor, with several firms investing heavily in research and development to introduce next-generation diagnostic platforms.

Market Trends and Future Outlook

The global market is witnessing several notable trends that are shaping its future trajectory. The adoption of point-of-care testing is increasing rapidly, offering faster diagnostic results and facilitating early intervention. Additionally, the integration of artificial intelligence and digital health tools is enhancing diagnostic accuracy and enabling real-time monitoring of disease progression.

Another emerging trend is the growing application of home-based testing kits, providing patients with convenience and encouraging proactive health management. This trend aligns with the broader movement toward personalized medicine, where patients are increasingly empowered to monitor their health conditions.

As healthcare systems worldwide shift their focus toward preventive and precision medicine, demand for fecal calprotectin testing is expected to surge. Governments and healthcare organizations are investing in awareness campaigns and screening programs to promote early diagnosis of gastrointestinal disorders, creating substantial growth opportunities for market players.

Conclusion

The fecal calprotectin test market is on a robust growth path, driven by technological innovation, rising disease prevalence, and increasing demand for non-invasive diagnostics. With a projected CAGR of 8.9% between 2025 and 2032, the market is set to nearly double in value, reaching US$9,623.7 million by the end of the forecast period. While challenges such as cost constraints and limited awareness persist, continuous advancements in testing technologies and expanding healthcare infrastructure are expected to propel the market forward. As key players pursue strategic collaborations and develop innovative diagnostic solutions, the fecal calprotectin test market is poised to play a pivotal role in shaping the future of gastrointestinal disease diagnostics worldwide.